GlaxoSmithKline PLC (GSK.LN) plans in the next few weeks to launch an effort to replace the entire board of Human Genome Sciences (HGSI), the target of a $2.6 billion offer by Glaxo which the U.S. company rejected, Reuters reported Wednesday on its website, citing people familiar with the situation.

Glaxo intends to nominate 12 directors to replace Human Genome's board, and has begun a search for candidates. Additionally, Glaxo is expected to extend its tender for Human Genome beyond June 7.

Glaxo declined comment to Reuters. Human Genome was not immediately available for comment, Reuters reported.

Full story at: www.reuters.com/article/2012/05/30/us-humangenome-gsk-idUSBRE84T0XR20120530

-Dow Jones Newswires; 212-416-2900

Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Human Genome Sciences Charts.
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Human Genome Sciences Charts.